Aptose Biosciences: Rises as Oppenheimer starts with outperform rating

Aptose Biosciences

25/01/2019 14:14

** U.S.-listed shares of Canadian drug developer  APTO.O 
rise 13.9 pct to $2.3 premarket
    ** Brokerage Oppenheimer initiates APTO coverage with
outperform rating (PT $6), citing commercial potential of co's
clinical-stage cancer drug CG-806 in two major indications -
acute myeloid leukemia and chronic lymphocytic leukemia 
    ** Oppenheimer considers CG-806 as two potent drugs rolled
into one
    ** All 4 brokerages covering the co rate the stock "buy" or
higher; median PT is $6.5 vs $8.5 in Oct 2018
    ** APTO had slumped 14.7 pct in 2018

 (Reporting by Manogna Maddipatla)
 ((Reuters Messaging:
manojna.kalyani.thomsonreuters.com@reuters.net))